Abstract
Objective: Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for ≥ 2 years. Methods: Patients with JIA-associated uveitis treated with IFX and ADA were managed by a standardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients were refractory to standard immunosuppressive treatment or were corticosteroid-dependent. Data recorded every 3 months were uveitis course, number/type of ocular flares and complications, drug-related adverse events (AE), and treatment switch or withdrawal. Data of patients treated for ≥ 2 years were analyzed by descriptive statistics. Results: Up to December 2014, 154 patients with ≥ 24 months followup were included in the study. Fifty-nine patients were treated with IFX and 95 with ADA. Clinical remission, defined as the absence of flares for > 6 months on treatment, was achieved in 69 patients (44.8%), with a better remission rate for ADA (60.0%) as compared to IFX (20.3%; p < 0.001). A significant reduction of flares was observed in all patients without difference between the 2 treatment modalities. The number of new ocular complications decreased in both groups but was lower for ADA (p = 0.015). No serious AE were recorded; 16.4% of patients experienced 35 minor AE and the incidence rate was lower with ADA than with IFX. Conclusion: At the 2-year followup, ADA showed a better efficacy and safety profile than IFX for the treatment of refractory JIA-associated uveitis.
| Original language | English |
|---|---|
| Pages (from-to) | 1167-1172 |
| Number of pages | 6 |
| Journal | Journal of Rheumatology |
| Volume | 45 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 1 2018 |
Fingerprint
Keywords
- Anti-TNF Agents
- Juvenile idiopathic arthritis
- Treatment
- Uveitis
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology
Cite this
Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis. / Cecchin, Vanessa; Zannin, Maria Elisabetta; Ferrari, Daniele; Pontikaki, Irene; Miserocchi, Elisabetta; Paroli, Maria P.; Bracaglia, Claudia; Marafon, Denise Pires; Pastore, Serena; Parentin, Fulvio; Simonini, Gabriele; De Libero, Cinzia; Falcini, Fernanda; Petaccia, Antonella; Filocamo, Giovanni; De Marco, Riccardo; La Torre, Francesco; Guerriero, Silvana; Martino, Silvana; Comacchio, Francesco; Muratore, Valentina; Martini, Giorgia; Vittadello, Fabio; Zulian, Francesco.
In: Journal of Rheumatology, Vol. 45, No. 8, 01.08.2018, p. 1167-1172.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis
AU - Cecchin, Vanessa
AU - Zannin, Maria Elisabetta
AU - Ferrari, Daniele
AU - Pontikaki, Irene
AU - Miserocchi, Elisabetta
AU - Paroli, Maria P.
AU - Bracaglia, Claudia
AU - Marafon, Denise Pires
AU - Pastore, Serena
AU - Parentin, Fulvio
AU - Simonini, Gabriele
AU - De Libero, Cinzia
AU - Falcini, Fernanda
AU - Petaccia, Antonella
AU - Filocamo, Giovanni
AU - De Marco, Riccardo
AU - La Torre, Francesco
AU - Guerriero, Silvana
AU - Martino, Silvana
AU - Comacchio, Francesco
AU - Muratore, Valentina
AU - Martini, Giorgia
AU - Vittadello, Fabio
AU - Zulian, Francesco
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Objective: Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for ≥ 2 years. Methods: Patients with JIA-associated uveitis treated with IFX and ADA were managed by a standardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients were refractory to standard immunosuppressive treatment or were corticosteroid-dependent. Data recorded every 3 months were uveitis course, number/type of ocular flares and complications, drug-related adverse events (AE), and treatment switch or withdrawal. Data of patients treated for ≥ 2 years were analyzed by descriptive statistics. Results: Up to December 2014, 154 patients with ≥ 24 months followup were included in the study. Fifty-nine patients were treated with IFX and 95 with ADA. Clinical remission, defined as the absence of flares for > 6 months on treatment, was achieved in 69 patients (44.8%), with a better remission rate for ADA (60.0%) as compared to IFX (20.3%; p < 0.001). A significant reduction of flares was observed in all patients without difference between the 2 treatment modalities. The number of new ocular complications decreased in both groups but was lower for ADA (p = 0.015). No serious AE were recorded; 16.4% of patients experienced 35 minor AE and the incidence rate was lower with ADA than with IFX. Conclusion: At the 2-year followup, ADA showed a better efficacy and safety profile than IFX for the treatment of refractory JIA-associated uveitis.
AB - Objective: Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for ≥ 2 years. Methods: Patients with JIA-associated uveitis treated with IFX and ADA were managed by a standardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients were refractory to standard immunosuppressive treatment or were corticosteroid-dependent. Data recorded every 3 months were uveitis course, number/type of ocular flares and complications, drug-related adverse events (AE), and treatment switch or withdrawal. Data of patients treated for ≥ 2 years were analyzed by descriptive statistics. Results: Up to December 2014, 154 patients with ≥ 24 months followup were included in the study. Fifty-nine patients were treated with IFX and 95 with ADA. Clinical remission, defined as the absence of flares for > 6 months on treatment, was achieved in 69 patients (44.8%), with a better remission rate for ADA (60.0%) as compared to IFX (20.3%; p < 0.001). A significant reduction of flares was observed in all patients without difference between the 2 treatment modalities. The number of new ocular complications decreased in both groups but was lower for ADA (p = 0.015). No serious AE were recorded; 16.4% of patients experienced 35 minor AE and the incidence rate was lower with ADA than with IFX. Conclusion: At the 2-year followup, ADA showed a better efficacy and safety profile than IFX for the treatment of refractory JIA-associated uveitis.
KW - Anti-TNF Agents
KW - Juvenile idiopathic arthritis
KW - Treatment
KW - Uveitis
UR - http://www.scopus.com/inward/record.url?scp=85051736730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051736730&partnerID=8YFLogxK
U2 - 10.3899/jrheum.171006
DO - 10.3899/jrheum.171006
M3 - Article
AN - SCOPUS:85051736730
VL - 45
SP - 1167
EP - 1172
JO - Journal of Rheumatology
JF - Journal of Rheumatology
SN - 0315-162X
IS - 8
ER -